Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zinfandel

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Gut instincts lead Takeda to GI pipeline success

Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy

- PMLiVE

Takeda begins development of COVID-19 plasma therapy

Drug will harness the antibodies of recovered coronavirus patients

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones

- PMLiVE

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Alzheimer's patients typically experience poor sleep

- PMLiVE

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

Gained conditional approval in China in November

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links